SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-24-043025
Filing Date
2024-04-09
Accepted
2024-04-09 16:42:47
Documents
18
Period of Report
2024-05-30

Document Format Files

Seq Description Document Type Size
1 DEF 14A crsp-20240409.htm   iXBRL DEF 14A 2480945
2 GRAPHIC img169346478_0.jpg GRAPHIC 19505
3 GRAPHIC img169346478_1.jpg GRAPHIC 6069
4 GRAPHIC img169346478_2.jpg GRAPHIC 66860
5 GRAPHIC img169346478_3.jpg GRAPHIC 35545
6 GRAPHIC img169346478_4.jpg GRAPHIC 37098
7 GRAPHIC img169346478_5.jpg GRAPHIC 555927
8 GRAPHIC img169346478_6.jpg GRAPHIC 366167
  Complete submission text file 0000950170-24-043025.txt   6262259

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT crsp-20240409.xsd EX-101.SCH 31321
21 EXTRACTED XBRL INSTANCE DOCUMENT crsp-20240409_htm.xml XML 414342
Mailing Address BAARERSTRASSE 14 ZUG V8 CH-6300
Business Address BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600
CRISPR Therapeutics AG (Filer) CIK: 0001674416 (see all company filings)

IRS No.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37923 | Film No.: 24833223
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)